Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
Stride, A; Shields, B; Gill-Carey, O; et al.Chakera, AJ; Colclough, K; Ellard, Sian; Hattersley, Andrew T.
Date: 1 January 2014
Journal
Diabetologia
Publisher
Springer Verlag
Publisher DOI
Related links
Abstract
Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological treatment and the impact of treatment on glycaemic control.
Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological treatment and the impact of treatment on glycaemic control.
Institute of Biomedical & Clinical Science
Collections of Former Colleges
Item views 0
Full item downloads 0